Dagens industri reports that Camurus, a pecialist pharmaceutical company, expects a profit of up to SEK 1.2 billion in 2025. For 4Q24, the company reports an operating profit of SEK 166 million, a significant improvement from a loss of SEK 28.5 million in the same period last year. Net income for the quarter was SEK 147 million, compared to a loss of SEK 15.2 million in 4Q23, with earnings per share at SEK 2.50. Net sales increased to SEK 553 million from SEK 375 million, and the board proposes no dividend for 2024, consistent with the previous year (ICE STOCCOLMA)

Fonte notizia: Dagens Industri